Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars
Authors:
- Alice Ruth LapthornALAlice Ruth Lapthorn
- Marcus Maximillian IlgMIMarcus Maximillian Ilg
- Justine Victoria SullivanJSJustine Victoria Sullivan
- Peter DziewulskiPDPeter Dziewulski
- Selim CellekSCSelim Cellek
Open Access
- 4 November 2022
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 937
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Antimycotic Ciclopirox Olamine in the Diabetic Environment Promotes Angiogenesis and Enhances Wound HealingPLOS ONE, 2011
- Novel therapeutic approaches for pulmonary fibrosisBritish Journal of Pharmacology, 2011
- CiclopiroxDrugs, 2010
- Keratinocyte–Fibroblast Interactions in Wound HealingJournal of Investigative Dermatology, 2007
- Fibroblasts and myofibroblasts: Their source, function and role in diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injuryBurns, 2006
- The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesisThe FASEB Journal, 2003
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Transforming Growth Factor-β in Thermally Injured Patients with Hypertrophic Scars: Effects of Interferon α-2bPlastic and Reconstructive Surgery, 1998